- Home
- FMY vs NRSN Comparison
FMY vs NRSN Comparison
Compare FMY & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMY
- NRSN
- Stock Information
- Founded
- FMY 2005
- NRSN 2017
- Country
- FMY United States
- NRSN Israel
- Employees
- FMY N/A
- NRSN N/A
- Industry
- FMY Finance/Investors Services
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- FMY Finance
- NRSN Health Care
- Exchange
- FMY Nasdaq
- NRSN Nasdaq
- Market Cap
- FMY 50.5M
- NRSN 58.8M
- IPO Year
- FMY N/A
- NRSN 2021
- Fundamental
- Price
- FMY $12.24
- NRSN $1.90
- Analyst Decision
- FMY
- NRSN Buy
- Analyst Count
- FMY 0
- NRSN 2
- Target Price
- FMY N/A
- NRSN $14.00
- AVG Volume (30 Days)
- FMY 10.1K
- NRSN 428.7K
- Earning Date
- FMY 01-01-0001
- NRSN 07-11-2025
- Dividend Yield
- FMY 6.98%
- NRSN N/A
- EPS Growth
- FMY N/A
- NRSN N/A
- EPS
- FMY N/A
- NRSN N/A
- Revenue
- FMY N/A
- NRSN N/A
- Revenue This Year
- FMY N/A
- NRSN N/A
- Revenue Next Year
- FMY N/A
- NRSN N/A
- P/E Ratio
- FMY N/A
- NRSN N/A
- Revenue Growth
- FMY N/A
- NRSN N/A
- 52 Week Low
- FMY $10.71
- NRSN $0.51
- 52 Week High
- FMY $12.17
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- FMY 67.54
- NRSN 48.49
- Support Level
- FMY $12.08
- NRSN $1.81
- Resistance Level
- FMY $12.05
- NRSN $2.35
- Average True Range (ATR)
- FMY 0.07
- NRSN 0.25
- MACD
- FMY 0.03
- NRSN -0.08
- Stochastic Oscillator
- FMY 94.44
- NRSN 16.07
About FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield and maturity.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.